This Is the Best Time to Eat Dinner, According to Experts
When is the best time to eat dinner? Between work, a commute, fitting in a quick workout, and potentially addressing other family needs, eating before the sun goes down is no simple task. But according to experts we spoke to, if possible, it may be what's best for your health.
Meet the Experts: Dana Cohen, M.D., integrative medical doctor and co-author of Quench, Michelle Routhenstein, M.S., R.D., preventive cardiology dietitian and certified diabetes educator, and Gretchen Zimmermann, R.D., vice president of clinical strategy at Vida Health.
Below, they explain why, share their favorite easy meal options, and weigh in on nighttime snacks that won't mess with your sleep.
When is the best time to eat dinner?
While doctors and dietitians acknowledge that schedules and things outside of our control all influence dinnertime, they seem to agree on an ideal window of time. 'Eating between 5 to 7 p.m. would be ideal,' says Dana Cohen, M.D., integrative medical doctor and co-author of Quench.
But, the exact time you dine has to do with your specific bedtime. Michelle Routhenstein, M.S., R.D., preventive cardiology dietitian and certified diabetes educator, recommends trying to eat two to three hours before bed because it helps with digestion, supports better sleep, and keeps blood sugar more stable. 'At night, the body becomes less efficient at handling sugar, so late meals can lead to higher blood sugar and may disrupt sleep in some people,' she says.
Gretchen Zimmermann, R.D., vice president of clinical strategy at Vida Health agrees with those recommendations. 'Your GI tract slows down at night as part of your natural circadian rhythm, so eating close to bedtime may delay gastric emptying, increase bloating, cause uncomfortable heartburn, and throw off your regularity,' she says.
You also want to avoid eating too early because going to bed hungry can disrupt your sleep quality, per the Mayo Clinic.
All of this said, if you just can't eat dinner in this window (maybe you have a night class or family obligation), stick to lighter meals (see below for more) and try not to lay down immediately after you finish eating.
Can eating dinner early help you lose weight?
Eating dinner at least three hours before bedtime may aid weight loss by supporting metabolic health and maintaining steady blood sugar levels, explains Routhenstein. Eating earlier also helps regulate hunger hormones, which can reduce late-night snacking, she adds, and therefore make weight gain less likely.
In fact, people who ate meals at 5 p.m. burned 60 more calories per day than those who ate dinner later, according to a study published in Cell Metabolism. The research participants who ate dinner later also stored fat differently and had higher levels of hunger. Another study, out of NYU Langone, found that eating earlier improves your metabolic health, which may help you lose weight. On the flip side, separate research, published in The American Journal of Clinical Nutrition, shows that eating later can prevent successful weight loss and lead to weight gain.
'More studies are needed to determine if eating early has a benefit for health and weight in the long term, but eating dinner early, between 5 and 7 p.m., or at least two to three hours before you go to bed may be a helpful strategy for supporting weight loss,' says Zimmermann. Another benefit of eating early is that you can squeeze in a 10- to 15-minute walk after dinner, which has positive benefits on blood sugar, digestion, and can provide a little extra calorie burn, she adds.
Benefits of eating dinner up to three hours before bed
Experts share other reasons you may want to consider having your last meal earlier in the evening.
Facilitates better sleep
Eating right before bedtime can have negative effects on the quality of your sleep, which means eating earlier has the potential to improve your rest and optimize your body's circadian rhythm.
Prevents heartburn
'Health conditions such as gastroesophageal reflux disease (GERD) require people to wait at least three hours after eating before lying down or going to sleep to prevent the contents of the stomach from going back up into the esophagus that may cause heartburn,' Dr. Cohen says.
Improves blood sugar levels
Research shows that eating earlier lowers blood glucose levels after dinner and throughout the night. This is because you don't metabolize glucose as efficiently when you eat out of phase with your circadian rhythm. According to the Mayo Clinic, diet, dehydration, stress, and more factors can cause blood sugar levels to rise, but having consistently high blood sugar (hyperglycemia) can lead to serious health complications.
What to eat for dinner
'Having a good balance of essential nutrients such as protein, fat, carbohydrates, vitamins, minerals, and water is important during any meal,' Dr. Cohen says. 'I love Mediterranean diet foods which include fruits, vegetables, whole grains, beans, and nuts, healthy fats like olive oil, and moderate amounts of fish and other lean proteins.'
One of Dr. Cohen's favorite dinners is escarole and beans drizzled with olive oil over crusty whole-grain bread. 'This light, delicious meal is easy to digest and filled with plant protein, good fats, and fiber making it a good choice for dinner,' she says.
Best nighttime snack options
If you end up feeling hungry after dinner, that's completely understandable. It's just important to choose healthy snacks that won't negatively impact your sleep. 'Try a light snack like chia pudding which is high in soluble fiber and omega-3s to support digestion and the microbiome,' Zimmermann suggests. 'Kiwis are a great source of soluble fiber, and when combined with a handful of walnuts, provide a gut-healthy snack.'
Routhenstein adds that cherries and pistachios may boost melatonin production, the hormone that regulates sleep. And yogurt with berries is another good choice because it contains tryptophan, an amino acid that promotes relaxation and better sleep.
Worst nighttime snack options
Unsurprisingly, nighttime snacks that experts recommend avoiding or minimizing are those that are generally not considered healthy, like ultra-processed chips or high-fat, high-sugar desserts, both of which can slow digestion and cause tummy trouble, experts say. Alcohol or excessive caffeine can dehydrate and mess with sleep, and large, protein-heavy meals eaten too late take longer to digest and may interfere with regularity.
The bottom line
In an ideal world, the experts recommend eating dinner two to three hours before bed. If you feel hungry after that, consider a light plant-based snack, preferably at least an hour before you plan to go to sleep.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Advanced Ophthalmology Technology Market to Hit Valuation of US$ 16.01 Billion by 2033
The market is rapidly advancing, driven by an aging population's needs. A clear segmentation is emerging hospitals focus on complex, high-margin procedures, while specialized centers increasingly absorb routine surgeries. Chicago, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global advanced ophthalmology technology market was valued at US$ 8.78 billion in 2024 and is expected to reach US$ 16.01 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025–2033. The future of the advanced ophthalmology technology market is being written today in research labs and clinical trials around the world. A robust pipeline of innovative treatments, particularly in areas like gene therapy for inherited and chronic eye diseases, holds the promise of not just managing but potentially reversing vision loss. The intense research activity is also reflected in the continuous stream of new patents being filed, protecting the intellectual property that will form the basis of next-generation devices and therapies. This forward-looking activity, combined with a growing and specialized workforce, ensures a long-term trajectory of growth and transformative breakthroughs for the industry. Download Sample Pages: The scale of innovation is evident in patent and clinical trial data. In 2024 alone, 1,393 international patents related to vision science were published. Ophthalmic Sciences, an innovator in the field, holds 6 total patents, with 3 of those being active globally. The clinical trial landscape is equally vibrant. The RGX-314 gene therapy trial for wet AMD has enrolled 465 patients, while the SOL-R registrational trial for AXPAXLI in the same condition has a target randomization of at least 555 patients. A search on reveals 22 active clinical studies focused on gene therapy for wet AMD. Supporting this innovation is a skilled workforce; the mean number of ophthalmologists per 100,000 inhabitants across Europe is 9.36, with nations like Italy having 12.28 practicing ophthalmology physicians per 100,000 persons in 2024. Niche markets are also showing strong growth, with the U.S. dry eye treatment devices market reaching approximately $99.7 million in 2024 to serve the around 16 million people diagnosed with Dry Eye Disease. Key Findings in Advanced Ophthalmology Technology Market Market Forecast (2033) US$ 16.01 billion CAGR 6.9% Largest Region (2024) North America (39%) By Type Diagnostic (58%) By End Use Hospitals (41%) Top Drivers Rising prevalence of age-related eye diseases boosts technology demand. Continuous technological advancements are improving diagnostic and surgical outcomes. Growing patient awareness regarding the importance of early eye diagnosis. Top Trends Artificial intelligence integration is revolutionizing diagnostics and treatment planning. Increasing surgeon and patient preference for minimally invasive procedures. Shift of routine surgeries from hospitals to specialized outpatient centers. Top Challenges The high acquisition and maintenance costs of advanced ophthalmic technologies. A growing shortage of skilled ophthalmologists to operate new equipment. Complex reimbursement policies and stringent regulatory approval processes. Financial Titans Dominating the Global Advanced Ophthalmology Technology Market Landscape The financial health of key industry players provides a powerful indicator of the market's robust vitality and sustained growth potential. These leading companies are demonstrating exceptional performance through impressive sales figures and strong operational cash flows, reflecting the high demand for their innovative products. Their financial strength not only solidifies their market position but also enables continued investment in the research and development that drives the entire sector forward. A close examination of their financial reports reveals a clear and compelling narrative of a thriving and profitable industry, setting a confident tone for future expansion and shareholder value in a competitive environment. Alcon, a global leader in the advanced ophthalmology technology market, showcases remarkable financial strength, reporting total net sales of $9.8 billion for the full year 2024. The performance was robust across its divisions, with Surgical net sales reaching $5.5 billion and Vision Care net sales hitting $4.3 billion. The company achieved a record cash from operations of $2.1 billion and a record free cash flow of $1.6 billion. A breakdown of 2024 quarterly performance further illustrates this momentum: Q1 sales were $2.4 billion, with $341 million in cash from operations and $229 million in free cash flow. Q2 sales increased to $2.5 billion, with Surgical net sales at $1.4 billion and Vision Care sales reaching $2.2 billion in the first half. Q3 saw net sales of $2.4 billion, with the Surgical segment contributing $1.34 billion, and Q4 sales were $2.5 billion. Bausch + Lomb also posted strong full-year 2024 revenues of $4.791 billion, with its Surgical segment accounting for $843 million and generating $232 million in cash flow from operations for the year. The company's third quarter revenue was $1.196 billion, with the surgical segment at $206 million and cash flow from operations at $154 million, while Q4 surgical revenue was $231 million. Topcon's Eye Care business reported first-half fiscal year 2024 sales of ¥37.1 billion (€224 million), with a full-year revenue forecast of ¥82.0 billion (€495 million). The combined North American and European half-year sales for Topcon were approximately ¥60 billion, underscoring the strong international demand within the advanced ophthalmology technology market. Unprecedented Surgical Volumes Propel Growth in the Advanced Ophthalmology Technology Market The sheer volume of surgical procedures performed worldwide is a primary engine powering the expansion of the market. An aging global population and the increased prevalence of conditions like cataracts are driving millions of patients to seek surgical solutions. Simultaneously, the introduction of safer, faster, and more effective minimally invasive techniques has broadened patient acceptance and accessibility. The statistics on cataract, LASIK, and SMILE procedures paint a vivid picture of a sector experiencing immense procedural demand. Such high volumes necessitate a continuous supply of advanced surgical equipment, implants, and consumables, creating a powerful and self-reinforcing cycle of growth and innovation. By 2025, an estimated 28 million cataract surgeries are performed annually across the globe, which translates to roughly 75,000 procedures every single day. The minimally invasive refractive procedure, Small Incision Lenticule Extraction (SMILE), has already surpassed 10 million procedures performed worldwide as of the end of 2024 in the advanced ophthalmology technology market. Since its FDA approval in 2016, an average of more than 1 million people have chosen SMILE each year, a procedure now offered by over 2,000 surgeons in 70 countries. The demand for intraocular lenses (IOLs) is staggering, with a projected 200 million patients requiring IOL implantation by 2025. In the United States alone, approximately 800,000 LASIK procedures are performed annually. Growth is also pronounced in developing markets; the estimated cataract surgery rate in China is expected to reach 350 per 100,000 people by 2025. Illustrating global outreach efforts, one specific aid project in Cambodia has already provided free surgery to 3,138 cataract patients, highlighting the vast unmet need that technology can address. Next-Generation Diagnostic and Monitoring Tools Redefine Patient Care and Market Demand Early and accurate diagnosis is the cornerstone of effective ophthalmology, and advanced diagnostic equipment is at the forefront of advanced ophthalmology technology market. Technologies like Optical Coherence Tomography (OCT) have become indispensable, providing high-resolution, cross-sectional images of the retina that enable the detection and management of numerous sight-threatening diseases. The growing prevalence of conditions such as diabetic retinopathy and age-related macular degeneration (AMD) is directly fueling the demand for these sophisticated diagnostic platforms. The market is responding with increasingly powerful and user-friendly devices, including handheld and automated units, that are expanding access to high-quality care from specialized clinics to primary care settings. The adoption rate of these technologies is reflected in strong sales figures, with 18,700 handheld OCT units sold globally in 2023. The clinical utility is immense, with over 50 million diabetes-related OCT scans performed annually. The technology's application in the advanced ophthalmology technology market is even extending beyond human medicine, with over 500 veterinary OCT devices now in use for animal diagnostics. Industry leader Topcon has sold over 20,000 units of its Maestro OCT system globally as of late 2023, a testament to the device's popularity and reliability. The urgency for such advanced diagnostic capability is underscored by daunting projections; approximately 200 million individuals are expected to be affected by AMD by the year 2040, creating a massive patient population in need of vigilant monitoring. Premium Intraocular Lenses Signal a Paradigm Shift in Cataract Surgery Outcomes The intraocular lens (IOL) segment has evolved far beyond simple vision correction, entering an era of premium technology that offers patients a range of lifestyle-enhancing benefits. Today's advanced IOLs can correct presbyopia, astigmatism, and other refractive errors, often reducing or eliminating a patient's dependence on glasses after cataract surgery. This shift towards premium, high-performance lenses represents a significant value-add in the cataract surgery space, driving revenue growth and patient satisfaction. As patient expectations rise, so does the demand for technologies that deliver superior visual outcomes, making the premium IOL sector a key growth area within the advanced ophthalmology technology market. The market's scale is substantial, with annual IOL lens unit shipments reaching 42 million in 2023, corresponding with the roughly 25 million cataract surgeries performed that year. The procedural efficiency in modern clinics further fuels this demand. High-volume cataract clinics now see surgeons implanting an average of 1,200 lenses per year. At an institutional level, surgical centers are now performing an average of 4,500 cataract cases annually. These high procedural volumes, combined with the increasing adoption of premium IOL technologies, create a powerful economic engine that supports ongoing innovation in lens design, materials, and functionality. Robust Investment and Venture Capital Fueling Future Ophthalmic Technology Market Breakthroughs A vibrant ecosystem of investment is crucial for nurturing the next wave of innovation, and the ophthalmology sector is attracting significant capital from diverse sources. Major corporations in the advanced ophthalmology technology market are channeling billions into research and development, while a dynamic venture capital landscape is providing essential funding for startups and emerging technologies. This influx of capital is accelerating the development of groundbreaking therapies, more advanced surgical devices, and sophisticated software platforms. The high level of merger and acquisition activity further signals a mature and attractive market where proven innovations are being rapidly integrated into larger commercial platforms, promising a future rich with transformative solutions. The financial commitment to innovation is clear. Alcon's R&D investment for the twelve months ending March 31, 2025, stood at an impressive $899 million, with annual R&D expenses for 2024 totaling $876 million. Across the industry, total investment in ophthalmology in 2024 exceeded $6.3 billion. The market also saw 18 merger and acquisition transactions in 2024, indicating strong consolidation and strategic growth activity. The venture capital pipeline is equally robust, with financing in ophthalmology for the first quarter of 2025 reaching $515.7 million across 21 transactions. As of May 2025, U.S. ophthalmology companies had already raised $597 million in equity funding through 15 rounds. Looking at a longer trend, the total venture capital investment in the ophthalmic devices sector over the last 10 years has amounted to a formidable $2.51 billion. Artificial Intelligence Integration Revolutionizes Diagnostics in the Advanced Ophthalmology Technology Market Artificial intelligence (AI) is rapidly transitioning from a theoretical concept to a practical and powerful clinical tool within the market. AI algorithms are now capable of analyzing retinal images with remarkable speed and accuracy, detecting early signs of diseases like diabetic retinopathy long before they might be caught by traditional methods. This technology is democratizing access to specialist-level diagnostics, enabling screening to be performed in primary care settings and reducing the burden on ophthalmologists. The efficiency and precision of AI are not just improving patient outcomes but also creating new operational efficiencies for healthcare systems. The real-world adoption of AI is accelerating in the advanced ophthalmology technology market. As of mid-2024, 198 AI-equipped cameras have been deployed across five U.S. health systems, covering a population of approximately 151,000 patients with diabetes. In the United States, three FDA-approved AI algorithms for diabetic retinopathy screening were available as of 2025. The clinical uptake is evident in reimbursement data, with more than 15,000 Medicare claims filed for AI diabetic retinopathy screening algorithms since 2022. The efficacy of these systems was proven in a clinical trial involving 900 patients, which led to FDA approval for one AI eye exam system. The speed of these platforms is a key advantage; scans using the AEYE-DS diabetic retinopathy algorithm are designed to produce actionable results in under 60 seconds. Surgical Laser Precision and Speed Setting New Benchmarks for Ophthalmic Procedures Modern excimer and femtosecond lasers are the technological cornerstones of refractive and cataract surgery, and continuous innovation is pushing the boundaries of what is possible in the advanced ophthalmology technology market. Today's surgical laser platforms offer unparalleled precision, speed, and safety, enabling surgeons to perform highly customized and predictable procedures. Advancements in eye-tracking technology, laser pulse frequency, and treatment algorithms are leading to better visual outcomes, faster recovery times, and an enhanced patient experience. These technological leaps are critical for meeting the high expectations of patients seeking freedom from corrective eyewear and are a major factor in the continued growth of the refractive surgery market. The Bausch + Lomb TENEO Excimer Laser Platform exemplifies this cutting-edge technology with its impressive performance metrics. The platform boasts an exceptionally fast ablation time of approximately 1.2 seconds per diopter, minimizing procedure time and improving patient comfort. Supporting this speed is an advanced eye-tracker that operates at an incredible 1,740 Hz, ensuring the laser remains perfectly centered on the eye even with involuntary movements. The TENEO laser itself operates at a high speed of 500 Hz, allowing for swift and highly precise corneal tissue ablation. These specific, quantifiable advancements are what define the leading edge of the advanced ophthalmology technology market, delivering tangible benefits to both surgeons and patients. Customize the Data Scope to Match Your Objectives: Strategic Private Equity Investment and Remote Care Reshape Ophthalmic Service Delivery The business landscape of ophthalmology is being actively reshaped by two powerful forces: strategic investment from private equity and the rise of remote care models. Private equity firms are increasingly drawn to the sector's stable growth and opportunities for consolidation, leading to a wave of practice acquisitions. This trend is creating larger, more efficient practice groups with greater resources for technology adoption. In parallel, tele-ophthalmology platforms are gaining traction, leveraging technology to conduct remote eye exams and consultations. This remote care model is expanding access to services, particularly in underserved areas, and creating new, flexible models for delivering eye care. The impact of private equity is significant in the advanced ophthalmology technology market, with over 330 private equity-backed physician practice management (PPM) transactions recorded in ophthalmology over the last five years. This consolidation trend is fundamentally changing the structure of service delivery in the market. Simultaneously, the telehealth revolution is making its mark. The remote examination platform from DigitalOptometrics, for instance, has already conducted over 2 million remote exams. This number highlights a clear and growing acceptance of remote technologies by both patients and providers, signaling a permanent shift in how ophthalmic services can be delivered and scaled. Global Advanced Ophthalmology Technology Market Major Players: Alcon Allergan Bausch + Lomb Carl Zeiss Meditec EssilorLuxottica Heidelberg Engineering HOYA Johnson Johnson Vision NIDEK CO., LTD Novartis Ophthotech Corporation Regeneron Pharmaceuticals, Inc. Roche Samsung Topcon Other Prominent Players Key Market Segmentation: By Type Diagnostic Therapeutic By End Use Hospitals Ambulatory Surgical Centers (ASCs) Ophthalmic Clinics Others By Region North America Europe Asia Pacific Middle East & Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
10 minutes ago
- Yahoo
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) i Sign in to access your portfolio

Yahoo
10 minutes ago
- Yahoo
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-- Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics' Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment. Novo Nordisk (NYSE:NVO) rose 1.4% premarket, while Eli Lilly gained 1.2%. Viking Therapeutics (NASDAQ:VKTX) plunged over 30% in premarket trading. The trial tested Viking's oral tablet VK2735, a dual GLP-1 and GIP receptor agonist, and met its primary endpoint, with patients losing up to 12.2% of body weight after 13 weeks versus 1.3% for placebo. However, a 28% treatment discontinuation rate among VK2735 recipients raised concerns, compared with 18% in the placebo group. Viking said 99% of gastrointestinal-related adverse events were mild or moderate, and an exploratory maintenance dosing arm indicated weight loss could be maintained at lower doses. Mizuho analyst Jared Holz said the data highlighted challenges relative to Eli Lilly's offerings. 'Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range — but over 72-weeks; a much longer trial, and therefore LLY looks far better head-to-head,' Holz wrote. He added that Viking would likely need pipeline improvements or enhanced formulations to regain investor interest. 'A tough day for retail investors ahead – that have been pumping this thing like a 1991 Reebok Dee Brown," concluded Holz. The results underscore the competitive pressure in the oral obesity market. Related articles Novo Nordisk, Eli Lilly rise after Viking obesity trial data Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Sign in to access your portfolio